Evidence map›Paper›PMID 33149585›Full record

ArticleInternational journal of nanomedicine2020

Efficacy of Combination Therapy with Linalool and Doxorubicin Encapsulated by Liposomes as a Two-in-One Hybrid Carrier System for Epithelial Ovarian Carcinoma.

Tae In Wi, Ji Eun Won, Chan Mi Lee, Jeong-Won Lee, Tae Heung Kang, Byung Cheol Shin, Hee Dong Han, Yeong-Min Park

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Tae In Wi *Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, South Korea.
Ji Eun Won *Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, South Korea.
Chan Mi LeeDepartment of Immunology, School of Medicine, Konkuk University, Chungju 380-701, South Korea.
Jeong-Won LeeDepartment of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.ORCID 0000-0002-6110-4909
Tae Heung KangDepartment of Immunology, School of Medicine, Konkuk University, Chungju 380-701, South Korea.
Byung Cheol ShinBio/Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, South Korea.
Hee Dong HanDepartment of Immunology, School of Medicine, Konkuk University, Chungju 380-701, South Korea.ORCID 0000-0002-3300-5575
Yeong-Min ParkDepartment of Immunology, School of Medicine, Konkuk University, Chungju 380-701, South Korea.
Konkuk University · KRKorea Research Institute of Chemical Technology · KRSamsung Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpithelial ovarian cancer (EOC) is a fatal gynecologic malignancy that is usually treated with chemotherapy after surgery. However, patients who receive chemotherapy experience severe side effects because of the inherent toxicity and high dose of chemotherapeutics. To overcome these issues, we suggest a combination therapeutic strategy using liposomes encapsulating linalool nanoemulsions (LN-NEs) and doxorubicin (DOX), a chemotherapeutic drug, to increase their synergistic antitumor efficacy and reduce the incidence of side effects from chemotherapeutics for EOC.

methodsThe physical properties of LN-NE-DOX-liposomes were characterized by light scattering with a particle size analyzer. Cell viability was determined by MTT assay. Therapeutic efficacy was evaluated in a mouse HeyA8 EOC tumor model of ovarian carcinoma. Additionally, biochemical toxicity was analyzed for levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and blood urea nitrogen (BUN) using BALB/c nude mice.

resultsThe size of the liposomes encapsulating LN-NEs and DOX (LN-NE-DOX-liposomes) was 267.0 ± 4.6 nm, with a loading efficiency of 55.1 ± 3.1% and 27.2 ± 0.9% for linalool and DOX, respectively. Cell viability after treatment with LN-NE-DOX-liposomes was significantly decreased compared to that of cells treated with DOX liposomes, and apoptosis was significantly increased. Additionally, LN-NE-DOX-liposomes significantly inhibited HeyA8 EOC tumor growth compared to that of the control (

conclusionThis study demonstrates that the production of LN-NE-DOX-liposomes is a pivotal approach for EOC treatment, suggesting a novel combination therapeutic strategy.

Indexed as

Acyclic MonoterpenesAnimalsApoptosisCarcinoma, Ovarian EpithelialCell Line, TumorCell ProliferationCell SurvivalCombined Modality TherapyDoxorubicinDrug CarriersEmulsionsFemaleHumansLiposomesMice, Inbred BALB CMice, NudeAcyclic MonoterpenesDoxorubicinDrug CarriersEmulsionslinaloolliposomal doxorubicinLiposomesPolyethylene Glycolscombination therapydoxorubicinlinaloolliposomeovarian carcinoma

Identifiers

PMID33149585
PMCPMC7605632
OpenAlexW3096579670

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.